Kazia治疗学和QIMR Berghofer正在研制NDL2,一种摧毁PD-L1的新型癌症药物,以克服对乳癌和肺癌的抗药性。 Kazia Therapeutics and QIMR Berghofer are developing NDL2, a new cancer drug that destroys PD-L1 to overcome resistance in advanced breast and lung cancers.

Kazia治疗机构与QIMR Berghofer合作开发了NDL2,这是一级PD-L1降解器,针对癌症细胞中的抗性蛋白质。 Kazia Therapeutics has partnered with QIMR Berghofer to develop NDL2, a first-in-class PD-L1 degrader targeting resistant forms of the protein in cancer cells. 与标准的免疫疗法不同的是,NDL2在整个细胞中消除了PD-L1,有可能克服对乳癌和肺癌的治疗阻力。 Unlike standard immunotherapies, NDL2 eliminates PD-L1 throughout the cell, potentially overcoming treatment resistance in advanced breast and lung cancers. 临床预科结果显示肿瘤大量减少,免疫反应有所改进,没有毒性。 Preclinical results show strong tumor reduction and improved immune response without toxicity. IND授权研究在六个月后开始,预计15个月后进行人类试验。 IND-enabling studies begin in six months, with human trials expected in 15 months.